Scorpio Bulkers Inc (SALT) Drops 16.13% on February 09

Equities Staff |

Scorpio Bulkers Inc (SALT) was one of the Russell 2000's biggest losers for Tuesday February 09 as the stock slid 16.13% to $2.08, a loss of $-0.4 per share. Starting at an opening price of $2.35 a share, the stock traded between $1.99 and $2.35 over the course of the trading day. Volume was 668,022 shares over 2,318 trades, against an average daily volume of 284,891 shares and a total float of 2.39 million.

The losses send Scorpio Bulkers Inc down to a market cap of $4.97 million. In the last year, Scorpio Bulkers Inc has traded between $35.39 and $2.33, and its 50-day SMA is currently $6.61 and 200-day SMA is $17.49.

Scorpio Bulkers Inc is engaged in acquiring and operating newbuilding drybulk carriers with fuel-efficient specifications and carrying capacities of greater than 30,000 dwt in the international shipping markets. It owns two Kamsarmax vessels.

Scorpio Bulkers Inc is based out of Monaco, and has some 3 employees. Its CEO is Emanuele A. Lauro.

For a complete fundamental analysis analysis of Scorpio Bulkers Inc, check out’s Stock Valuation Analysis report for SALT. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…


Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…